Tactile Systems Technology (TCMD) pays $3M for exclusive MyoSleeve VA/DoD distribution

Rhea-AI Filing Summary

Tactile Systems Technology, Inc. entered into an exclusive U.S. distribution agreement with ElastiMed, Inc. to distribute the MyoSleeve™ wearable, non-pneumatic compression device to Department of Veterans Affairs and Department of Defense patients across the United States. MyoSleeve, which has U.S. Food and Drug Administration 510(k) clearance for treating chronic swelling conditions, is a discreet, battery-powered lower-leg device designed for earlier stages of disease and as a complement to traditional pneumatic compression therapy.

Under the agreement, Tactile Systems paid $3 million upfront to ElastiMed, obtained exclusive distribution rights within VA and DoD systems, and committed to minimum purchase, marketing, and sales promotion obligations while leveraging its existing sales and patient-support infrastructure to commercialize MyoSleeve.

8-K Event Classification

3 items: 7.01, 8.01, 9.01

3 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Figures

Upfront payment: $3 million

1 metrics

Upfront payment $3 million Paid by Tactile Systems to ElastiMed for exclusive VA and DoD U.S. distribution rights for MyoSleeve

Key Terms

exclusive distribution agreement, 510(k) clearance, electroactive polymer technology, pneumatic compression device

4 terms

exclusive distribution agreement regulatory

"entered into an exclusive distribution agreement with ElastiMed, Inc. to bring MyoSleeve"

A contract in which a manufacturer or rights holder gives one distributor the sole right to sell a product or service in a particular territory or channel. For investors, it matters because exclusivity can boost predictable sales, margin stability and market reach for the parties involved, but it also concentrates risk—if the distributor underperforms or the agreement ends, revenue can drop sharply. Think of it like appointing a single shop to be the only place in town to sell a popular item.

510(k) clearance medical

"MyoSleeve has received U.S. Food and Drug Administration 510(k) clearance"

A 510(k) clearance is a U.S. regulatory approval that lets a medical device be sold because it is shown to be substantially similar to an already-legal device; think of it as a passport saying the new product is close enough to a known item to enter the market without a full, lengthy review. For investors, 510(k) clearance signals faster, lower-cost market access and reduced regulatory risk compared with new, untested device pathways, which can materially affect timelines, costs and revenue prospects.

electroactive polymer technology technical

"MyoSleeve uses electroactive polymer technology to deliver dynamic compression"

A class of synthetic plastics that change shape, size, conductivity or other properties when exposed to an electrical signal, functioning like a soft, artificial muscle or switch. They are used to make sensors, tiny actuators, flexible electrodes and energy-harvesting or storage components, especially where lightweight, bendable materials are needed. Investors track them because they enable new products, manufacturing and regulatory paths, intellectual property and potential markets in medical devices, robotics and flexible electronics.

pneumatic compression device medical

"complementary treatment to a traditional pneumatic compression device"

A pneumatic compression device is a medical device that uses inflatable sleeves or cuffs and timed air pressure cycles to squeeze limbs and promote blood flow, like a mechanical massage that helps prevent blood clots and reduces swelling. Investors care because these devices are sold to hospitals, clinics and patients, and their commercial value depends on clinical effectiveness, regulatory approvals, reimbursement rules and adoption by healthcare providers, all of which affect sales and revenue.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

Available on EDGAR 07/13/2026 - 09:23 AM Accepted by SEC EDGAR 07/13/2026 - 09:23 AM Learn about SEC filing dates

FAQ

What did Tactile Systems Technology (TCMD) announce on July 13, 2026?

Tactile Systems Technology announced an exclusive U.S. distribution agreement with ElastiMed for the MyoSleeve™ wearable compression device, focused on Department of Veterans Affairs and Department of Defense patients across the United States.

How much is Tactile Systems Technology (TCMD) paying under the ElastiMed agreement?

In connection with the exclusive distribution rights, Tactile Systems made an upfront payment of $3 million to ElastiMed. The company also agreed to certain minimum purchase obligations and to support marketing and sales promotion for MyoSleeve.

What is MyoSleeve in the Tactile Systems Technology (TCMD) agreement?

MyoSleeve is a discreet, wearable non-pneumatic compression device for the lower leg. It is battery-powered, uses electroactive polymer technology, and delivers dynamic intermittent compression while being worn beneath clothing during daily activities.

For which patients will Tactile Systems Technology (TCMD) distribute MyoSleeve?

Tactile Systems will distribute MyoSleeve to VA and DoD patients across the United States. The device targets appropriately selected patients with chronic swelling, including earlier disease stages, and is available by prescription as determined by treating clinicians.

Does MyoSleeve in the Tactile Systems Technology (TCMD) deal have FDA clearance?

Yes. MyoSleeve has received U.S. Food and Drug Administration 510(k) clearance and is indicated for treating chronic swelling conditions, including chronic edema, lymphedema, and venous insufficiency, within the scope described in the agreement.

How does MyoSleeve fit into Tactile Systems Technology’s (TCMD) product portfolio?

According to the company, MyoSleeve expands its chronic swelling portfolio by offering a wearable option for earlier-stage patients and as a complementary therapy to traditional pneumatic compression devices, aligning with its strategy to broaden patient-focused treatment options.

false 0001027838 TACTILE SYSTEMS TECHNOLOGY INC 0001027838 2026-07-13 2026-07-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)  July 13, 2026

TACTILE SYSTEMS TECHNOLOGY, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-37799		41-1801204
(State or other jurisdiction of		(Commission		(I.R.S. Employer
incorporation)		File Number)		Identification No.)

3701 Wayzata Blvd, Suite 300, Minneapolis, MN 55416

(Address of principal executive offices) (Zip Code)

(612) 355-5100

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, Par Value $0.001 Per Share	TCMD	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).  ¨ Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 7.01. Regulation FD Disclosure.

On July 13, 2026, Tactile Systems Technology, Inc. (“we,” “us,” and “our”) issued a press release announcing a distribution agreement. A copy of the press release is attached hereto as Exhibit 99.1.

In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933 or the Securities Exchange Act of 1934, except as shall be expressly set forth by specific reference in that filing.

Item 8.01. Other Events.

On July 13, 2026, we announced that we have entered into an exclusive distribution agreement with ElastiMed, Inc. to bring MyoSleeve™, its discreet, wearable non-pneumatic compression device for the lower leg, to Department of Veterans Affairs (“VA”) and Department of Defense (“DoD”) patients across the United States. MyoSleeve expands our established market-leading portfolio by providing a new treatment option for appropriately selected patients in earlier stages of chronic swelling who may not yet require more intensive compression therapy. MyoSleeve may also be appropriate as a complementary treatment to a traditional pneumatic compression device and for patients who struggle with conservative therapy, or those with mobility-limiting cases.

Wrapped around the calf with the ability to be worn beneath clothing, MyoSleeve uses electroactive polymer technology to deliver dynamic compression through flexible bands that contract in sequence. The battery-powered device is designed as an all-in-one therapy option, operating without tubing, cords, or an external controller, and quietly delivers intermittent therapy while patients go about daily activities. MyoSleeve has received U.S. Food and Drug Administration 510(k) clearance and is indicated for the treatment of chronic swelling, including chronic edema, lymphedema, and venous insufficiency.

Under the agreement, we hold exclusive U.S. distribution rights for MyoSleeve within the VA and DoD systems. In connection with these exclusive distribution rights, we made an upfront payment of $3 million to ElastiMed. We also committed to certain minimum purchase obligations and marketing and sales promotion as we support ElastiMed’s growth. We expect to leverage our established sales organization, billing and payment expertise, and patient support infrastructure to drive MyoSleeve commercialization and support ongoing market access initiatives. MyoSleeve is available by prescription, and appropriate patient selection is determined by the treating clinician.

Legal Notice Regarding Forward-Looking Statements

This report contains forward-looking statements, including expectations regarding the distribution agreement and related actions. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “continue,” “confident,” “outlook,” “guidance,” “project,” “goals,” “look forward,” “poised,” “designed,” “plan,” “return,” “focused,” “prospects” or “remain” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties outside of our control that can make such statements untrue, including, but not limited to, our ability to obtain reimbursement from third-party payers for our products; adverse economic conditions, including inflation, rising interest rates or a recession; the adequacy of our liquidity to pursue our business objectives; price increases for supplies and components; wage and component price inflation; loss of a key supplier or other supply chain disruptions; entry of new competitors and/or competitive products; compliance with and changes in federal, state and local government laws and regulations; technological obsolescence of, or quality issues with, our products; our ability to expand our business through strategic acquisitions; our ability to integrate acquisitions and related businesses; the effects of current and future U.S. and foreign trade policy and tariff actions; or the inability to carry out research, development and commercialization plans. In addition, other factors that could cause actual results to differ materially are discussed in our filings with the SEC. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. We undertake no obligation to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

EXHIBIT INDEX

Exhibit No.		Description
99.1		Press Release dated July 13, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	TACTILE SYSTEMS TECHNOLOGY, INC.
Date: July 13, 2026	By:	/s/ Elaine M. Birkemeyer
		Elaine M. Birkemeyer
		Chief Financial Officer

Exhibit 99.1

Tactile Medical Enters Exclusive U.S. Distribution Agreement with ElastiMed for its MyoSleeve™ Wearable Compression Device for VA and DoD Patients

Discreet, Battery-Powered Device Reaches Patients at Earlier Stages of Disease Progression

MINNEAPOLIS, July 13, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced it has entered into an exclusive distribution agreement with ElastiMed, Inc. to bring MyoSleeve™, its discreet, wearable non-pneumatic compression device for the lower leg, to Department of Veterans Affairs (VA) and Department of Defense (DoD) patients across the United States. MyoSleeve expands Tactile Medical’s established market-leading portfolio by providing a new treatment option for appropriately selected patients in earlier stages of chronic swelling who may not yet require more intensive compression therapy. MyoSleeve may also be appropriate as a complementary treatment to a traditional pneumatic compression device and for patients who struggle with conservative therapy, or those with mobility-limiting cases.

Wrapped around the calf with the ability to be worn beneath clothing, MyoSleeve uses electroactive polymer technology to deliver dynamic compression through flexible bands that contract in sequence. The battery-powered device is designed as an all-in-one therapy option, operating without tubing, cords, or an external controller, and quietly delivers intermittent therapy while patients go about daily activities. MyoSleeve has received U.S. Food and Drug Administration 510(k) clearance and is indicated for the treatment of chronic swelling, including chronic edema, lymphedema, and venous insufficiency.

Under the agreement, Tactile Medical holds exclusive U.S. distribution rights for MyoSleeve within the VA and DoD systems. In connection with these exclusive distribution rights, the Company made an upfront payment of $3 million to ElastiMed. The Company also committed to certain minimum purchase obligations and marketing and sales promotion as it supports ElastiMed’s growth. The Company expects to leverage its established sales organization, billing and payment expertise, and patient support infrastructure to drive MyoSleeve commercialization and support ongoing market access initiatives. MyoSleeve is available by prescription, and appropriate patient selection is determined by the treating clinician.

“Our agreement with ElastiMed adds a differentiated, wearable compression option to Tactile Medical’s portfolio and reflects our strategy of expanding access to patient-focused solutions across the continuum of chronic swelling care,” said Sheri Dodd, Chief Executive Officer of Tactile Medical. “For the right patient, MyoSleeve offers unobtrusive compression therapy that fits into daily life, giving patients the freedom to stay mobile while engaged in their own care.”

"Partnering with Tactile Medical gives MyoSleeve a direct path to certain patients with chronic swelling who want to stay active while getting the treatment they need,” said Omer Zelka, Chief Executive Officer of ElastiMed. “It is the first ambulatory all-in-one, cable-free, clinical-grade solution for patients with venous and lymphatic conditions. This partnership enables the first commercial introduction of MyoSleeve through a trusted and market-leading medical device partner."

"Compression therapy is not one-size-fits-all. Clinicians achieve the best outcomes when they have a range of options that can be matched to disease severity, anatomy, and lifestyle," said Tony Gasparis, MD, Chief Medical Officer of Tactile Medical. "MyoSleeve introduces an important new option for appropriately selected patients with lower-leg swelling, offering active compression that is well-suited for earlier stages of disease, where consistent therapy adherence is key to slowing disease progression. Importantly, MyoSleeve is designed to complement — not replace — advanced pneumatic compression therapies, which remain the standard of care for patients with more extensive or advanced disease."

For more information about MyoSleeve, please visit https://tactilemedical.com/myosleeve/.

About Tactile Systems Technology, Inc. (DBA Tactile Medical)

Tactile Medical is a leader in developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic inflammatory lung disease by helping them live better and care for themselves. Tactile Medical collaborates with clinicians to expand clinical evidence, raise awareness, increase access to care, reduce overall healthcare costs and improve the quality of life for tens of thousands of patients each year.

About ElastiMed, Inc.

ElastiMed is a commercial-stage medical device company developing wearable therapeutic devices based on electroactive polymer (EAP) technology, designed to deliver dynamic compression in a comfortable, low-profile, and easy-to-use form.

Investor Inquiries:

Sam Bentzinger

Gilmartin Group

investorrelations@tactilemedical.com

Filing Exhibits & Attachments

4 documents

Press Releases

• EX-99.1 EXHIBIT 99.1 9.1 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.0 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 33.4 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 21.8 KB